Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318670 | 1.00 | NNMT (0.37) | NNMTTDO2GABRPGABRDGABRA1 | |
| SCHEMBL11996768 | 0.77 | NNMT (0.50) | NNMTTDO2GABRPGABRDGABRA1 | |
| SCHEMBL14990136 | 0.77 | NNMT (0.46) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8118182 | 0.77 | DRD1 (0.39) | NNMTTDO2GABRPGABRDGABRA1 | |
| SCHEMBL25352523 | 0.76 | — | — | |
| SCHEMBL16116088 | 0.76 | NNMT (0.35) | NNMTTDO2GABRPGABRDGABRA1 | |
| SCHEMBL16114910 | 0.75 | NNMT (0.41) | NNMTTDO2GABRPGABRDGABRA1 | |
| SCHEMBL20606492 | 0.75 | NNMT (0.37) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL25347775 | 0.75 | CNR2 (0.42) | NNMTTDO2GABRPGABRDGABRA1 | |
| SCHEMBL1162059 | 0.75 | NNMT (0.41) | NNMTGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-116113635-B | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | PFIZER INC. (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2024255412-A1 | SPIRO HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4161927-B9 | SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4444708-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118510780-A | Spiro heterocyclic compounds and uses thereof | 广州必贝特医药股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3223820-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-22 | — | — | US | disclosed |
| EP-3099687-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016085780-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
| WO-2015116886-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015051241-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | CSPP1, PRNP, RPLP2 | NNMT 3779/4885TDO2 3638/4885GABRP 3674/4885 |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | NNMT 2869/4885TDO2 964/4885GABRP 2126/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | NNMT 2869/4885TDO2 964/4885GABRP 2126/4885 |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | NNMT 1388/4885TDO2 4557/4885GABRP 3159/4885 |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI2, F2, TFPI | NNMT 4807/4885TDO2 2245/4885GABRP 2244/4885 |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | NNMT 2869/4885TDO2 964/4885GABRP 2126/4885 |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | NNMT 2479/4885TDO2 1875/4885GABRP 594/4885 |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, PSEN1 | NNMT 560/4885TDO2 2352/4885GABRP 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.